Allakos is a clinical stage biotechnology company that has been developing therapeutics that target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases
We aim to create monoclonal antibodies that activate or block inhibitory receptors on immune cells. Activating inhibitory receptors allows us to directly inhibit cells involved in disease pathogenesis and, in the setting of allergy and inflammation, has the potential to reduce inflammation. In addition, activating inhibitory receptors can counteract multiple activation pathways and thereby has the potential to reduce inflammation more broadly than approaches targeting a single activation pathway. In the setting of proliferative diseases, blocking the inhibitory function of the receptors could restore the immune cell’s ability to identify and kill proliferative cells.